Frontline Plc/ CY0200352116 /
5/30/2024 10:10:00 PM | Chg. -0.76 | Volume | Bid10:49:22 PM | Ask10:49:22 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
27.96USD | -2.65% | 2.42 mill. Turnover: 57.22 mill. |
27.75Bid Size: 300 | 28.40Ask Size: 500 | 6.26 bill.USD | 7.71% | 9.54 |
GlobeNewswire
5/28
Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hosp...
GlobeNewswire
5/27
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
5/24
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
GlobeNewswire
5/23
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual M...
GlobeNewswire
5/23
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
5/21
Dalrada Financial Corporation Healthcare Subsidiary, Genefic, Inc., Acquires IV Services Infusion Ph...
GlobeNewswire
5/20
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
GlobeNewswire
5/20
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for it...
GlobeNewswire
5/16
Harri Announces Product Innovation Designed to Propel the Frontline Employee Experience and Restaura...
GlobeNewswire
5/16
Dalrada Financial Corporation Files Form 10-Q, Announces Third Quarter Revenue of $10.3 Million
GlobeNewswire
5/14
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-17215...
GlobeNewswire
5/14
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML